This week, the overall grades of five Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Geron‘s (NASDAQ:GERN) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Geron Corporation is a biopharmaceutical company that discovers and develops therapeutic and diagnostic products to treat cancer and other age-related degenerative diseases including spinal cord injury, heart failure and diabetes. In Portfolio Grader’s specific subcategories of Equity, Cash Flow, and Sales Growth, GERN also gets an F. The stock price has dropped 27.7% over the past month, worse than the 3.3% increase the Nasdaq has seen over the same period of time. For a full analysis of GERN stock, visit Portfolio Grader.
Anacor Pharmaceuticals (NASDAQ:ANAC) earns a D this week, falling from last week’s grade of C. Anacor Pharmaceuticals focuses on discovering, developing, and commercializing small-molecule therapeutics derived from boron chemistry platform. The stock gets F’s in Equity, Cash Flow, and Sales Growth. The price of the company has increased 5.4% from a month ago. To get an in-depth look at ANAC, get Portfolio Grader’s complete analysis of ANAC stock.
Oncolytics Biotech (NASDAQ:ONCY) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Oncolytics Biotech discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 20.9% over the past month. For more information, get Portfolio Grader’s complete analysis of ONCY stock.
Immunomedics (NASDAQ:IMMU) gets weaker ratings this week as last week’s D drops to an F. Immunomedics develops, manufactures, and sells diagnostic imaging and therapeutic products. The stock gets F’s in Earnings Growth and Sales Growth. As of Sept. 19, 12.2% of outstanding Immunomedics shares were held short. The stock currently has a trailing PE Ratio of 364. For a full analysis of IMMU stock, visit Portfolio Grader.
YM BioSciences‘s (AMEX:YMI) rating weakens this week, dropping to a D versus last week’s C. YM BioSciences is a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. The stock gets F’s in Equity and Sales Growth. Over the past month, the price of YMI shot up 11.8%. To get an in-depth look at YMI, get Portfolio Grader’s complete analysis of YMI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.